There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara Inc (SVRA), Novavax (NVAX) and Tetraphase (TTPH) with bullish sentiments.
Savara Inc (SVRA)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Savara Inc today and set a price target of $6. The company’s shares closed yesterday at $10.57.
According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.2% and a 39.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Savara Inc with a $15.67 average price target, a 48.2% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
Novavax (NVAX)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax today and set a price target of $10. The company’s shares closed yesterday at $4.93, close to its 52-week low of $4.64.
Bernardino commented:
“We derived our price target of $10 using DCF methodology with a 30% discount rate, 2% terminal growth rate, and a clinical program probability-of-success of 72%. Risks to our investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, unproven commercialization strategy, failure of products to show sufficient differentiation in targeted therapeutic indications, patent expiry or invalidation, and potential to raise additional funds under poor market conditions.”
According to TipRanks.com, Bernardino is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.7% and a 28.6% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Innovus Pharmaceuticals Inc, Can-Fite BioPharma, and Seres Therapeutics.
Novavax has an analyst consensus of Moderate Buy, with a price target consensus of $18.36, a 272.4% upside from current levels. In a report issued on June 11, Ladenburg also maintained a Buy rating on the stock with a $2 price target.
Tetraphase (TTPH)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Tetraphase today and set a price target of $1.50. The company’s shares closed yesterday at $0.74, close to its 52-week low of $0.71.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.3% and a 33.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Tetraphase has an analyst consensus of Moderate Buy, with a price target consensus of $5.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
